Event > Conference >
ESTIV 2024
The 22nd International Congress of the European Society of Toxicology In Vitro (ESTIV 2024) will be organised in Prague, Czech Republic, from 3rd to 6th June 2024.
The ESTIV2024 Congress theme is Application of NAMs in Drug Discovery and Drug and Chemical Safety Assessment.
Thank you for visiting us at ESTIV on stand #29!
Presentation
A Sensitive and Robust Human Liver Microphysiological System for Assessing Drug-Induced Liver Injury
The PhysioMimix® liver-on-a-chip accurately predicts human-relevant drug-induced liver injury (DILI), a leading cause of acute liver failure and therapeutic candidate attrition. The microphysiological system (MPS) is comprised of primary human liver parenchymal and nonparenchymal cells that are cultured into 3D microtissues, on an engineered scaffold, under perfusion, for up to two weeks. The assay was qualified using thirteen reference compounds (IQ MPS Consortium), and the concentrations of three soluble biomarkers – LDH, urea, and albumin were measured to assess the sensitivity and robustness of the in vitro model. Our liver MPS demonstrated better sensitivity and specificity than traditional 2D primary hepatocyte cultures and even some standard non-MPS 3D models, matching clinical data, and highlighting the clinical translatability of our liver-on-a-chip models.
Date: Tuesday 4 June, 2024
Time: 12:20pm
Track: 3b Organ-on-a-Chip and Microphysiological Systems (11:00 – 13:00)
Presented by: Dr. Ovidiu Novac, CN Bio
Our Team at ESTIV 2024
Ovi
Dr Ovidiu Novac is a Senior Scientist at CN Bio and a knowledgeable organ-on-a-chip (OOC) expert. Ovi performed as lead biological scientist in the NASH-in-a-Box project, is a knowledgeable organ-on-a-chip (OOC) expert, and has experience in assessing drug induced liver injury in vitro. Ovi has a background in the developmental stage of pharmaceutical and dermatological formulations and their performance assessment on human skin tissue ex vivo (topical and transdermal), and for strategic planning for further evaluation. During time spent in the pharma industry he contributed to delivering high quality results used for marketing purposes and in regulatory submissions. Ovi holds a BSc in biomaterials and prosthetic technologies and a PhD in chemistry and has been involved in research on controlled drug delivery systems since 2006.
Atefeh
Dr Atefeh Mobasseri, Field Application Scientist at CN Bio, has an extensive background in tissue engineering and regenerative medicine. Before joining CN Bio, she gained a PhD in Biomedical materials from the University of Manchester and carried out postdoctoral roles at the University of Manchester and Kings College London investigating the interaction, and effect, of 3D scaffolds on cellular behaviour. Since joining CN Bio, she has been supporting their European customers in using CN Bio’s range of PhysioMimix® systems to generate high content, human-relevant, data.
Adrian
A seasoned business developer with extensive commercial experience in the life science sector, Adrian Rea joined CN Bio as the European Director of Sales in June 2022. He brings valuable experience in the 3D cell culture market from his most recent role at InSphero, where he was responsible for developing business opportunities in European and Asian markets. He was previously Sales Director at Enzo Life Sciences, where he managed the restructuring of the global distributor sales channels and expanding the European sales operations. Adrian graduated from the University of Glasgow and received his PhD in pharmacology from Glasgow Caledonian University.